CATEGORIES

Industry - Academia Collaboration For The Early Development Of Biopharmaceuticals

With an aim of creating a globally competitive biopharmaceutical industry that addresses the country’s major concerns around barriers to affordable healthcare, Innovate in India (I3) program was launched by Dr Harsh Vardhan, Union Minister of Science & Technology on 30th June 2017 in New Delhi.

PE Giants Eyeing Stake At Mankind Worth Crores

Big private equity firms and sovereign wealth funds are exploring a purchase deal share worth at least Rs 5,000-crore ($750-million) in India’s fifth largest drug maker Mankind Pharma.

Promoting Affordable Healthcare

WITH MORE THAN 25 YEARS OF EXPERIENCE IN HEALTHCARE, TERRI BRESENHAM HAS MADE SEVERAL CONTRIBUTIONS TOWARDS ADDRESSING GLOBAL HEALTH ISSUES

Assisting Breast Cancer Diagnosis

AFTER LEADING THE CANCER DRUG DISCOVERY AND MULTI-DISCIPLINARY RESEARCH ON ‘POINT-OF-CARE’ DIAGNOSTICS AT RENOWNED COMPANIES, DR MANJIRI M. BAKRE IS NOW DEVELOPING COST EFFECTIVE AND RELIABLE TESTS FOR PERSONALIZED CANCER TREATMENT.

Transforming Hair & Skin Care

A DOCTORATE IN TRICHOLOGY HELPED DR BANI ANAND TO TAKE HAIR & SKIN CARE TREATMENT FROM NON-SURGICAL COMPETENCIES TO SURGICAL TREATMENT OPTIONS.

Enhancing Clinical Drug Developments

WITH HER 20 YEARS OF EXPERIENCE, BINDHYA CARIAPPA IS WORKING ON PUTTING INDIA ON THE GLOBAL CLINICAL TRIAL MAP.

Agilent In Agreement With Agendia For Cancer Diagnostics

Agilent Technologies Inc. and Agendia, Inc. have jointly announced an agreement to expand their relationship to include the development of an RNA Seq kit version of Agendia’s currently marketed Mamma Print and Blueprint tests.

Nanoparticles For Treating Eye Infections

Scientists at the Hyderabad-based CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) have developed a novel way to treat fungal keratitis.

Global Pharma Continues To See Potential In Investing In R&D In India

Innovative biopharmaceutical companies around the world continue to strive to accelerate the pace of innovation and deliver effective medicines to patients quickly and efficiently. By investing more time, energy, and resources in collaboration across the R&D ecosystem and leveraging more sophisticated research and manufacturing tools, these companies in India continue to invest in R&D and advance the science forward.

Competition Is Getting Fierce Among The 'Health Startups' In India

Medical care is just a click away but this has also blown a trumpet of online combat between these startups. Currently, it may look like a wide field to play in but in the coming years, there will be more players joining these online battle and then it will become a cut throat competition

GST To Have Constructive Effect On The Pharma And Healthcare Sectors

Though healthcare and pharma sectors hailed the announcement of GST rates, by saying that GST will encourage local manufacturing sector to step into producing products that will be more affordable for the local consumers. But with introduction of GST ayurvedic medicines will be taxed at 12 per cent from the current tax rate of 7 per cent, which has disappointed the Ayurvedic medicines industry badly.

There Is Need To Increase Awareness About Clinical Research That Has Done Good For Patients

There Is Need To Increase Awareness About Clinical Research That Has Done Good For Patients

The New Challenges Demand That We Make Innovative Strategies: J P Nadda

The New Challenges Demand That We Make Innovative Strategies: J P Nadda

Thermo Fisher Scientific India Conducts Genetic Solutions World Tour

As part of the Genetics Solutions World Tour, Thermo Fisher India recently organized seminars in Delhi & Bengaluru to showcase our market leadership and establish new opportunities for Sanger sequencing, Next Generation Sequencing (NGS) and Microarray.

Special News

Kiran Medical Systems Bags Healthcare Award

Supplier News

IISc Researchers Propose A More Effective Treatment For Tuberculosis

“Private Sector, Government Need To Work Together To Make Healthcare Accessible In Rural India”

For the first time National Heath Policy is talking about the preventive healthcare and wellness. From the statement point of view, it is really a commendable thing but now it has to be translated on to the ground. Harish Pillai COO, Indus Health Plus in an interaction with BioSpectrum India talks about why preventive healthcare is the need of the hour and how it can be successful.

Make In India' - A Major Boon To Medical Technology Industry

Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 165 countries for the last 20 years. Today, Trivitron Healthcare, through successful inorganic synergies with local and global firms, has a revenue turnover of Rs 750 crore. BioSpectrum India spoke to Dr GSK Velu, Chairman & Managing Director, Trivitron Healthcare Group of Companies to about the status of medical technology market in India and competition coming from Chinese medical devices.Excerpts of the interview

Association Of Indian Medical Device Industry (AIMED) Recommendations

Association Of Indian Medical Device Industry (AIMED) Recommendations

Medical Devices Rules, 2017 Opens Up Enormous Opportunities

The new Medical Devices Rules, 2017 seek to remove regulatory bottlenecks to make in India, facilitate ease of doing business while ensuring availability of better medical devices for patient care and safety. The rules will also regulate a much larger set of medical devices under a framework customized for medical devices. The stakeholders are hoping that the system will be industry friendly and will indeed create an ecosystem that will enable to boost medical technology innovation and manufacturing in the country.

Natco Pharma Plans API Expansion With More Investment

Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient (API) and intermediates manufacturing facility in Tamil Nadu. The company is looking at investing in its existing facility, in Thiruvallur District.

IP In Start-Up Ecosystem

In this age of innovation and technology, Intellectual Property (IP) is an essential element for an organization to sustain and flourish over long periods of time. This is particularly applicable for organizations which rely heavily on R&D to develop technology based solutions for existing problems, and the biotech startup community is no different.

India To Bounce Back As Clinical Research Hub

India was considered as an all-time favoured destination for clinical trials. Most of the outsourced studies are phase III studies where India has a diverse pool of patients. After 2010 there was major setback in the CRO industry in India. Drug Controller General of India (DCGI) approvals were delayed and multinational sponsors stepped back outsourcing studies to India. But slowly post 2016 DCGI has been generous enough in proving approvals and online application system has brought a lot of difference. Indian Clinical Trial market and clinical trial services is expected to grow significantly along with trends.